Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies

Kelsie L. Becklin; Garrett M. Draper; Rebecca A. Madden; Mitchell G. Kluesner; Tomoyuki Koga; Miller Huang; William A. Weiss; Logan G. Spector; David A. Largaespada; Branden S. Moriarity; Beau R. Webber

doi:10.1089/crispr.2022.0032

Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies

Kelsie L. Becklin, Garrett M. Draper, Rebecca A. Madden, Mitchell G. Kluesner, Tomoyuki Koga, Miller Huang, William A. Weiss, Logan G. Spector, David A. Largaespada, Branden S. Moriarity, Beau R. Webber

Research output: Contribution to journal › Review article › peer-review

3 Scopus citations

Abstract

Advances in genome and tissue engineering have spurred significant progress and opportunity for innovation in cancer modeling. Human induced pluripotent stem cells (iPSCs) are an established and powerful tool to study cellular processes in the context of disease-specific genetic backgrounds; however, their application to cancer has been limited by the resistance of many transformed cells to undergo successful reprogramming. Here, we review the status of human iPSC modeling of solid tumors in the context of genetic engineering, including how base and prime editing can be incorporated into "bottom-up"cancer modeling, a term we coined for iPSC-based cancer models using genetic engineering to induce transformation. This approach circumvents the need to reprogram cancer cells while allowing for dissection of the genetic mechanisms underlying transformation, progression, and metastasis with a high degree of precision and control. We also discuss the strengths and limitations of respective engineering approaches and outline experimental considerations for establishing future models.

Original language	English (US)
Pages (from-to)	517-535
Number of pages	19
Journal	CRISPR Journal
Volume	5
Issue number	4
DOIs	https://doi.org/10.1089/crispr.2022.0032
State	Published - Aug 1 2022

Bibliographical note

Funding Information:
B.R.W. acknowledges funding from NIH grants R21CA237789, R21AI163731, P01CA254849 Alex's Lemonade Stand Foundation, Children's Cancer Research Fund, and Rein in Sarcoma. Research in the Moriarity Lab is supported by NIH grants P50CA136393, P01CA254849, R01AI161017, and R01AI146009. D.A.L. acknowledges funding from the American Cancer Society Research Professor Award and the National Institutes of Health (R01NS115438). M.H. acknowledges funding from the Wright Trust Foundation, The Saban Research Institute, and National Institutes of Health (R00CA197484). Research in the Weiss lab is supported by NIH grants R01CA255369, R01NS106155, R01CA221969, P01CA217959, P30CA082103, P50CA097257, U01CA217864, U54CA243125, Alex's Lemonade Stand, The Brain Tumour Charity, Cancer Research UK grant A28592, St. Baldrick, and Samuel G. Waxman Foundations; and the Evelyn and Mattie Anderson Chair. Figures were created using BioRender (BioRender.com).

Publisher Copyright:
© 2022 Mary Ann Liebert, Inc., publishers.

PubMed: MeSH publication types

Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1089/crispr.2022.0032

Find It

Find It at U of M Libraries

Cite this

Becklin, K. L., Draper, G. M., Madden, R. A., Kluesner, M. G., Koga, T., Huang, M., Weiss, W. A., Spector, L. G., Largaespada, D. A., Moriarity, B. S., & Webber, B. R. (2022). Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies. CRISPR Journal, 5(4), 517-535. https://doi.org/10.1089/crispr.2022.0032

@article{81da767edabb4e7584d687cb7221e032,

title = "Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies",

abstract = "Advances in genome and tissue engineering have spurred significant progress and opportunity for innovation in cancer modeling. Human induced pluripotent stem cells (iPSCs) are an established and powerful tool to study cellular processes in the context of disease-specific genetic backgrounds; however, their application to cancer has been limited by the resistance of many transformed cells to undergo successful reprogramming. Here, we review the status of human iPSC modeling of solid tumors in the context of genetic engineering, including how base and prime editing can be incorporated into {"}bottom-up{"}cancer modeling, a term we coined for iPSC-based cancer models using genetic engineering to induce transformation. This approach circumvents the need to reprogram cancer cells while allowing for dissection of the genetic mechanisms underlying transformation, progression, and metastasis with a high degree of precision and control. We also discuss the strengths and limitations of respective engineering approaches and outline experimental considerations for establishing future models.",

author = "Becklin, {Kelsie L.} and Draper, {Garrett M.} and Madden, {Rebecca A.} and Kluesner, {Mitchell G.} and Tomoyuki Koga and Miller Huang and Weiss, {William A.} and Spector, {Logan G.} and Largaespada, {David A.} and Moriarity, {Branden S.} and Webber, {Beau R.}",

note = "Funding Information: B.R.W. acknowledges funding from NIH grants R21CA237789, R21AI163731, P01CA254849 Alex's Lemonade Stand Foundation, Children's Cancer Research Fund, and Rein in Sarcoma. Research in the Moriarity Lab is supported by NIH grants P50CA136393, P01CA254849, R01AI161017, and R01AI146009. D.A.L. acknowledges funding from the American Cancer Society Research Professor Award and the National Institutes of Health (R01NS115438). M.H. acknowledges funding from the Wright Trust Foundation, The Saban Research Institute, and National Institutes of Health (R00CA197484). Research in the Weiss lab is supported by NIH grants R01CA255369, R01NS106155, R01CA221969, P01CA217959, P30CA082103, P50CA097257, U01CA217864, U54CA243125, Alex's Lemonade Stand, The Brain Tumour Charity, Cancer Research UK grant A28592, St. Baldrick, and Samuel G. Waxman Foundations; and the Evelyn and Mattie Anderson Chair. Figures were created using BioRender (BioRender.com). Publisher Copyright: {\textcopyright} 2022 Mary Ann Liebert, Inc., publishers.",

year = "2022",

month = aug,

day = "1",

doi = "10.1089/crispr.2022.0032",

language = "English (US)",

volume = "5",

pages = "517--535",

journal = "CRISPR Journal",

issn = "2573-1599",

publisher = "Mary Ann Liebert Inc.",

number = "4",

}

TY - JOUR

T1 - Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies

AU - Becklin, Kelsie L.

AU - Draper, Garrett M.

AU - Madden, Rebecca A.

AU - Kluesner, Mitchell G.

AU - Koga, Tomoyuki

AU - Huang, Miller

AU - Weiss, William A.

AU - Spector, Logan G.

AU - Largaespada, David A.

AU - Moriarity, Branden S.

AU - Webber, Beau R.

N1 - Funding Information: B.R.W. acknowledges funding from NIH grants R21CA237789, R21AI163731, P01CA254849 Alex's Lemonade Stand Foundation, Children's Cancer Research Fund, and Rein in Sarcoma. Research in the Moriarity Lab is supported by NIH grants P50CA136393, P01CA254849, R01AI161017, and R01AI146009. D.A.L. acknowledges funding from the American Cancer Society Research Professor Award and the National Institutes of Health (R01NS115438). M.H. acknowledges funding from the Wright Trust Foundation, The Saban Research Institute, and National Institutes of Health (R00CA197484). Research in the Weiss lab is supported by NIH grants R01CA255369, R01NS106155, R01CA221969, P01CA217959, P30CA082103, P50CA097257, U01CA217864, U54CA243125, Alex's Lemonade Stand, The Brain Tumour Charity, Cancer Research UK grant A28592, St. Baldrick, and Samuel G. Waxman Foundations; and the Evelyn and Mattie Anderson Chair. Figures were created using BioRender (BioRender.com). Publisher Copyright: © 2022 Mary Ann Liebert, Inc., publishers.

PY - 2022/8/1

Y1 - 2022/8/1

N2 - Advances in genome and tissue engineering have spurred significant progress and opportunity for innovation in cancer modeling. Human induced pluripotent stem cells (iPSCs) are an established and powerful tool to study cellular processes in the context of disease-specific genetic backgrounds; however, their application to cancer has been limited by the resistance of many transformed cells to undergo successful reprogramming. Here, we review the status of human iPSC modeling of solid tumors in the context of genetic engineering, including how base and prime editing can be incorporated into "bottom-up"cancer modeling, a term we coined for iPSC-based cancer models using genetic engineering to induce transformation. This approach circumvents the need to reprogram cancer cells while allowing for dissection of the genetic mechanisms underlying transformation, progression, and metastasis with a high degree of precision and control. We also discuss the strengths and limitations of respective engineering approaches and outline experimental considerations for establishing future models.

AB - Advances in genome and tissue engineering have spurred significant progress and opportunity for innovation in cancer modeling. Human induced pluripotent stem cells (iPSCs) are an established and powerful tool to study cellular processes in the context of disease-specific genetic backgrounds; however, their application to cancer has been limited by the resistance of many transformed cells to undergo successful reprogramming. Here, we review the status of human iPSC modeling of solid tumors in the context of genetic engineering, including how base and prime editing can be incorporated into "bottom-up"cancer modeling, a term we coined for iPSC-based cancer models using genetic engineering to induce transformation. This approach circumvents the need to reprogram cancer cells while allowing for dissection of the genetic mechanisms underlying transformation, progression, and metastasis with a high degree of precision and control. We also discuss the strengths and limitations of respective engineering approaches and outline experimental considerations for establishing future models.

UR - http://www.scopus.com/inward/record.url?scp=85138604144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138604144&partnerID=8YFLogxK

U2 - 10.1089/crispr.2022.0032

DO - 10.1089/crispr.2022.0032

M3 - Review article

C2 - 35972367

AN - SCOPUS:85138604144

SN - 2573-1599

VL - 5

SP - 517

EP - 535

JO - CRISPR Journal

JF - CRISPR Journal

IS - 4

ER -

Developing Bottom-Up Induced Pluripotent Stem Cell Derived Solid Tumor Models Using Precision Genome Editing Technologies

Abstract

Bibliographical note

PubMed: MeSH publication types

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this